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Letter to the Editor
Mendelian Randomization
Estimates May Be Inflated
Ference et al. (1), using a Mendelian randomization approach,
show that the genetic effect of a unit change in low-density
lipoprotein (LDL) on coronary heart disease (CHD) is much
larger than the increase in risk per unit LDL seen prospectively in
cohort studies or the similar-sized decrease in risk per unit LDL
seen with effective interventions. The authors ascribe this differ-
ence to the lifelong effects of low LDL and suggest that earlier
intervention to reduce LDL could be beneficial. This is quite
possible. However, the Mendelian randomization estimate given
for the genetic effect of a unit change in LDL on CHD depends
on the assumption that the association of genetic variants with
LDL is constant across life or changes consistently with the
association of genetic variants with CHD. If some aspect of aging
or ill health reduced only the genetic association with LDL, the
genetic effect of a unit change in LDL on CHD would be
overstated (2) because the Mendelian randomization genetic effect
of LDL on CHD was estimated as the association of genetic
variants with CHD divided by the association of genetic variants
with LDL. Most of the studies providing the estimate of genetic
variants with LDL concern middle-aged people (1), in whomLDL levels may be affected by factors such as aging, ill health,
treatment, or body mass index, potentially attenuating the true
association of genetic variants with LDL. Few studies have
examined whether genetic associations with LDL vary with aging
and ill health, but evidence exists that shows the association of
some of the relevant genetic variants with LDL can vary substan-
tially with age (3,4), with weaker associations seen in older people.
Thus, the findings reported may not be inconsistent with the
effects of a unit change in LDL on CHD seen in cohort studies
and randomized control trials. Instead of indicating the life-long
effects of LDL, these findings may be the result of reverse
causality weakening the genetic association with specifically
LDL and thereby inflating the estimate.
More generally, this study illustrates the difficulty with inter-
preting such as Mendelian randomization estimates. Mendelian
randomization studies are most suitable for refuting causality
rather than establishing the exact size of a causal effect. First, such
a Mendelian randomization estimate will only indicate the true
size of a causal effect if the level of over- or under-estimation of the
genetic associations with the exposure and outcome are similar
(and nondifferential). If the observed genetic association with the
exposure is more understated than that with the outcome, then the
estimate may be too large. Conversely, if the observed genetic
association with the exposure is less understated than that with the
outcome, then the estimate may be too small. Second, an exposure
could appear to be causal in a Mendelian randomization study if it
were a marker of an intermediate factor between genetic variants
and exposure that also caused the exposure and outcome. As such,
Mendelian randomization estimates should be interpreted as
hypothesis testing, that is, able to disprove a postulated causal
effect, rather than indicating the size or existence of a postulated
causal effect.
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Reply
We agree with Dr. Schooling and colleagues that interpreting the
magnitude of the association between a modifiable exposure such
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disease within the context of a Mendelian randomization study can
be complex. Indeed, it was initially unclear whether the much-
larger-than-expected reduced risk of coronary heart disease
(CHD) reported in the original PCSK9 studies was caused by the
effect of lifelong exposure to lower LDL-C or to the combination
of lower LDL-C and other pleiotropic effects mediated by this
polymorphism (1). For this reason, we specifically sought to
evaluate the association between lifelong exposure to lower
LDL-C and the risk of CHD mediated by polymorphism in a
variety of different genes, each of which presumably affects circu-
lating LDL-C levels by a different mechanism or biological
pathway.
We found that each polymorphism included in our study was
associated with a highly consistent effect on the risk of CHD when
measured per unit lower of LDL-C with no evidence for hetero-
geneity of effect (2). In addition, we found an essentially identical
magnitude of effect when we estimated the association between
lifelong exposure to lower LDL-C and the risk of CHD by using
a genetic LDL-C score, which measures the effect of lifelong
exposure to lower LDL-C mediated by the combined effect of the
included polymorphism. The practice of combining multiple
instruments for a modifiable exposure into a single instrument to
estimate the magnitude of a causal effect is common in the field of
econometrics (3). Indeed, the magnitude of the association be-
tween lifetime exposure to lower LDL-C and the risk of CHD
observed in our study has now been independently confirmed using
separate genetic LDL-C scores composed of different combina-
tions of polymorphism in two other studies (4,5).
The repeated replication of the same magnitude of effect per
unit of lower LDL-C for each individual polymorphism included
in our study, and for multiple different genetic LDL-C scores
measured in different populations, strongly argues that our esti-
mate of the magnitude of the effect of lifelong exposure to lower
LDL-C on the risk of CHD is unlikely to be confounded by
population stratification, linkage disequilibrium, pleiotropy, or
other systematic bias, such as attenuation of effect with age as
suggested by Dr. Schooling and colleagues because it would be
implausible that each of these associations was affected by 1 or
more of these biases in the same direction with the same magni-
tude of effect. Furthermore, in multiple metaregression analyses,
we found no evidence for effect modification of age on the
association between circulating LDL-C levels and any of the
polymorphism included in our study (including rs646776). There-
fore, we believe that it is very unlikely that the results of our study
were inflated by the potential attenuation of LDL-C genetic
associations with age as suggested by Schooling et al. Instead, we
believe that the results of our study, and those of other studies,
provide robust naturally randomized evidence for the magnitude of
the association between lifelong exposure to lower LDL-C and the
risk of CHD.
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How to Balance Cardiometabolic
Benefits and Risks of Statins
The paper by Waters et al. (1) is timely and important in
delineating overall risk-benefit profiles of statin therapy in
patients with risk factors for diabetes. However, this study
reminds physicians of the important issue of risk-benefit con-
cept in treating patients with drugs. Therefore, it is important
to look over the hazard ratio (HR) of new onset diabetes
(NOD) and cardiovascular events (CVE) in patients by lower
dose (atorvastatin 10 mg or simvastatin 20 to 40 mg) versus
higher dose (atorvastatin 80 mg) statin therapy according to the
number of NOD risk factors: fasting blood glucose 100 mg/dl,
fasting triglycerides 150 mg/dl, body mass index 30 kg/m2, and
istory of hypertension. In Figure 1 of Waters et al. (1), in risk
actor 0, HRs of NOD and CVE are 0.96 and 0.95 by lower dose
ersus higher dose statin therapy; in risk factor 1, HRs of NOD
nd CVE are 0.97 and 0.82 by lower dose versus higher dose statin
herapy; in risk factor 2, HRs of NOD and CVE are 1.15 and 0.85
y lower dose versus higher dose statin therapy; in risk factor 3,
Rs of NOD and CVE are 1.31 and 0.82 by lower dose versus
igher dose statin therapy; in risk factor 4, HRs of NOD and CVE
re 1.36 and 0.65 by lower dose versus higher dose statin therapy;
nd overall, HRs of NOD and CVE are 1.16 and 0.85 by lower
ose versus higher dose statin therapy, respectively (1). Therefore,
t is true that higher dose statin therapy significantly reduced CVE;
owever, when both HRs are considered simultaneously, it seems
hat higher dose statin therapy does not have any benefit compared
ith lower dose statin therapy.
Consistent with this observation, recent clinical and meta-
nalysis studies have demonstrated that the effect of statins to
nduce type 2 diabetes is dose-dependent (2,3). Hypercholes-
erolemic patients receiving high dose atorvastatin (80 mg)
eveloped greater insulin resistance, higher fasting insulin
evels, and higher HbA1c levels when compared with patients
eceiving the low-dose atorvastatin (10 mg) or placebo, sug-
esting that high-dose statin therapy may have greater adverse
ffects on glucose homeostasis than low-dose therapy (2). A
ecent meta-analysis demonstrated that intensive-dose statins
ncreased the risk of developing type 2 diabetes by 1.12 (95%
